Asia Pacific Insomnia Market Summary
As per Market Research Future Analysis, the Asia Pacific Insomnia Market was valued at USD 0.14 Billion in 2023 and is projected to grow to USD 0.20 Billion by 2032, with a CAGR of 8.12% from 2024 to 2032. Insomnia, the most prevalent sleep disorder, affects a significant portion of the population, particularly women and younger individuals. Factors such as increased alcohol, caffeine, and tobacco consumption, along with psychological and behavioral issues, are driving the rise in insomnia cases. The market is further supported by technological advancements and rising healthcare expenditures. However, a lack of education and awareness may hinder growth.
Key Market Trends & Highlights
The Asia Pacific Insomnia Market is witnessing significant growth driven by various factors.
- Market Size in 2023: USD 0.14 Billion
- Projected Market Size by 2032: USD 0.20 Billion
- CAGR from 2024 to 2032: 8.12%
- Japan holds the largest market share, with 1 in 5 people affected by insomnia.
Market Size & Forecast
2023 Market Size | USD 0.14 Billion |
2024 Market Size | USD 0.18 Billion |
2032 Market Size | USD 0.20 Billion |
Major Players
Key players include Takeda Pharmaceutical Company, Pfizer, Inc., Eisai, Co., Merck & Co Inc, Sanofi, and GlaxoSmithKline Plc.